Koyfin Home > Directory > Health Care > Revance Therapeutics > Cash from Investing Activities

Revance Therapeutics Cash from Investing Activities Chart (RVNC)

Revance Therapeutics annual/quarterly Cash from Investing Activities from 2012 to 2020.
  • Revance Therapeutics Cash from Investing Activities for the quarter ending June 06, 2020 was $94m a 99.02% increase of 93m year over year
  • Revance Therapeutics Cash from Investing Activities for the last 12 months ending June 06, 2020 was $20m a 47.48% increase of 10m year over year
  • Revance Therapeutics Annual Cash from Investing Activities for 2019 was $-18m a -508.38% increase of 89m from 2018
  • Revance Therapeutics Annual Cash from Investing Activities for 2018 was $-107m a 210.99% decrease of -226m from 2017
  • Revance Therapeutics Annual Cash from Investing Activities for 2017 was $119m a 163.56% increase of 194m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Cash from Investing Activities Data

06/2020$94m
03/2020$-106m
12/2019$31m
09/2019$1m
06/2019$54m
03/2019$-103m
12/2018$59m
09/2018$30m
06/2018$4m
03/2018$-200m

Annual RVNC Cash from Investing Activities Data

2019$-18m
2018$-107m
2017$119m
2016$-75m
2015$-56m
2014$-7m
2013$-6m
2012$0m
2011$0m